Overview:
In this presentation, we will demonstrate HPLC methodologies tailored for a range of GLP-1 agonist therapeutics. Our discussion will include the principles and applications of Size Exclusion Chromatography (SEC) for aggregation analysis, as well as reversed-phase techniques for the characterization of related substances and the development of stability-indicating methods across multiple GLP-1 drug products.
Key Learning Points:
- Learn how to apply Size Exclusion Chromatography (SEC) theory and principles to analyze peptide aggregation.
- Identify and evaluate key considerations in developing and optimizing Reversed Phase HPLC methods for the separation of closely related peptide substances.
- Find how to differentiate the outcomes of forced degradation studies in peptide drug products from known related substances.
Analytical Strategies for GLP-1 Agonists: Aggregation, Related Substances and Stability Workflows
Overview:
In this presentation, we will demonstrate HPLC methodologies tailored for a range of GLP-1 agonist therapeutics. Our discussion will include the principles and applications of Size Exclusion Chromatography (SEC) for aggregation analysis, as well as reversed-phase techniques for the characterization of related substances and the development of stability-indicating methods across multiple GLP-1 drug products.
Key Learning Points:
- Learn how to apply Size Exclusion Chromatography (SEC) theory and principles to analyze peptide aggregation.
- Identify and evaluate key considerations in developing and optimizing Reversed Phase HPLC methods for the separation of closely related peptide substances.
- Find how to differentiate the outcomes of forced degradation studies in peptide drug products from known related substances.
